FDA ClearanceFDA clearance of first-line treatment of major depressive disorder (MDD) in adolescent patients will expand Neuronetics’ total addressable market by 35%, and the company is already gaining interest from providers prior to its launch.
Market PositionNeuroStar is now the first and only transcranial magnetic stimulation (TMS) treatment cleared for the treatment of major depressive disorder in patients aged 15-21.
Revenue GrowthThe company is on the path to profitability with its revenue growth, margin profile, and operating expense improvement.